+ Watch MYGN
on My Watchlist
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Short Ratio is unusual high.
personalized medicine - the way to go !
It relies on BRCA testing, which will see extreme price pressure from payors
Great company in a high growth sector ( diagnostics )
Very impressive sales growth, return on assets, and zero debt. The provision in the Health Care Act that does not allow discrimination based on pre-existing conditions is really going to support diagnostic companies like this. The fear of having the results used against participants appears to have been eliminated.
biotech w/ profits!! This company has minimal debt & phenomenal ROIC and ROE. They are currently on a pullback, but it is time to jump in!
Too high, too fast.
I have some shares.
I just have a feeling. This is going to 60 a share in 3 years. Amazing product line until the patents run out and then business will become competitive. Revs increasing setting up for the perfect storm on performance
Bought rival. Beat estimates.
Sold fundamentals. Why do doctors want to know your family history? To provide preventive guidance. The diagnostic tests this company provides quantify this information in a very specific way. Even though Medicare will no longer pay for these tests it in the younger patients not the elderly that are the target market. Affordable Care Act. In time the insurance companies will embrace this concept if it proves to cut cost of healthcare. The market over reacted to the court ruling. 47% of float shorted. Huge short squeeze on any good news.
I think the huge dip is an overreaction. I order 5 of these a month in my practice, and while there are others coming up with similar tests, there will be a lag time.
Myriad Genetics, Inc. MYGN. Molecular diagnostic company. Interesting relatively newer niche field. Return on Invested Capital (ROIC) of 21.57 twelve-trailing-months is quite attractive. No debt/equity going back to 2004 indicates strong financial health. Trailing price/earnings ratio of 14.0 is lowest historical P/E going back 5 years to 2008. Market cap of 1.99 Billion leaves room to grow and/or be acquired. Currently priced 24.77, trading at lower end of 52 week range of 22.20 - 38.27.
Massive Diagnostics Rx Cmpany!
BRCA1/2 testing competition from other companies that will utilize next gen sequencing techniques. Supreme court ruling eliminates Myriad's monopoly
Lost BRCA1/BRCA2 patents. They are going down.
The Affordable Care Act and publicity over A Jolie's surgery due to BRACA genes will boost sales of the BRACA genetics test, of which Myriad is the only producer.
Magic formula with good morningstar grades and high CAPS rating
Porte and ZZ.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions